Mass spectrometry based proteomic profiling for pancreatic cancer

Journal of the Pancreas

Volumn 11, Issue 5, 2010, Pages 422-426

  Pawa, Nikhil ^a   Wright, James M ^a   Arulampalam, Tan H A ^a  

^a IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Biological markers; CA 19 9 antigen; Pancreatic neoplasms; Proteomics

Indexed keywords

ALBUMIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN; K RAS PROTEIN; MACROGLOBULIN; TRANSFERRIN; TUMOR MARKER;

CANCER REGISTRY; COST EFFECTIVENESS ANALYSIS; CRYSTALLIZATION; DIAGNOSTIC ACCURACY; DOWN REGULATION; EARLY DIAGNOSIS; EDITORIAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVERALL SURVIVAL; PANCREAS CANCER; POINT MUTATION; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEOMICS; SAFETY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SURVIVAL TIME; UPREGULATION; ADENOCARCINOMA; EVALUATION; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; METABOLOME; METHODOLOGY; PANCREAS TUMOR; PATHOLOGY; VALIDATION STUDY;

ADENOCARCINOMA; HUMANS; MASS SPECTROMETRY; METABOLOME; PANCREATIC NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 77958003219     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Editorial

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics 2008. CA Cancer J Clin 2008; 58:71-96. [PMID 18287387]
2. Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005; 9:922-927. [PMID 16137585]
3. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996; 83:625-631. [PMID 8689203]
4. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications and outcomes. Ann Surg 1997; 226:248-257. [PMID 9339931]
5. Moossa AR, Gamagani RA. Diagnosis and staging of pancreatic neoplasms. Surg Clin North Am 1995; 75:871-890. [PMID 7660251]
6. Hruban RH, van Mansfield AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143:545-554. [PMID 8342602]
7. Hruban RH, Offerhaus GJ, Kern SE, Goggins M, Wilentz RE, Yeo CJ. Tumor-suppressor genes in pancreatic cancer. J Hepatobiliary Pancreat Surg 1998; 5:383-391. [PMID 9931387]
8. Bhattacharyya S, Siegel ER, Petersen GM, Chari ST, Suva LJ, Haun RS. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 2004; 6:674-686. [PMID 15548376]
9. Egawa S, Takeda K, Fukuyama S, Motoi F, Sunamura M, Matsuno S. Clinicopathological aspects of small pancreatic cancer. Pancreas 2004; 28:235-240. [PMID 15084963]
10. Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 2005; 4:523-533. [PMID 15684406]
11. Goggins MG. The molecular diagnosis of pancreatic cancer. In: Von Hoff DD, Evans DB, Hruban RH. Eds. Pancreatic Cancer. 1st ed. Sudbury: Jones and Bartiett Publishers 2005: 251-64.
12. Bloomston M, Zhou JX, Rosemary AS, Frankel W, Muro-Cacho CA, Yeatman TJ. Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res 2006; 66: 2592-2599. [PMID 16510577]
13. Seibert V, Ebert MPA, Buschmann T. Advances in clinical cancer proteomics: SELDI-Tof-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic 2005; 4:16-26. [PMID 15975261]
14. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48:1296-1304. [PMID 12142387]
15. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577. [PMID 11867112]
16. Banez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003; 170:442-446. [PMID 12853795]
17. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath, S et al. Serum diagnosis of pancreatic adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10:860-868. [PMID 14871961]
18. Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T, Kikuchi S, et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 2005; 65:10613-10622. [PMID 16288055]
19. Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, et al. Prediction of pancreatic cancer by serum biomarkers using surface enhanced laser desorption/ionization-based decision tree classification. Oncology 2005; 68:79-86. [PMID 15864000]
20. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005; 11:1110-1118. [PMID 15709178]
21. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007; 34:205-214. [PMID 17312459]
22. Kojima K, Asmellash S, Klug CA, Grizzle WE, Mobley JA, Christein JD. Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer. J Gastrointest Surg 2008; 12:1683-1690. [PMID 18709425]
23. Ma N, Ge CL, Luan FM, Hu CJ, Li YZ, Liu YF. Establishment of serum protein pattern model for screening pancreatic cancers by SELDI-TOF-MS technique. Zhonghua Wai Ke Za Zhi 2008; 46:932-935. [PMID 19035154]
24. Liu D, Cao L, Yu J, Que R, Jiang W, Zhou Y, et al. Diagnosis of pancreatic adenocarcinoma using protein chip technology. Pancreatology 2009; 9:127-135. [PMID 19077463]
25. Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidanel L, et al. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med 2009; 47:713-723. [PMID 19426140]
26. Guo J, Wang W, Liao P, Lou W, Ji Y, Zhang C, et al. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci 2009; 100:2292-2301. [PMID 19775290]
27. Rodland K. Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin Biochem 2004; 37:579-583. [PMID 15234239]
28. De Noo ME, Tollenaar RAEM, Deelder AM, Bouwman LH. Current status and prospects of clinical proteomics studies on detection of colorectal cancer: Hopes and fears. World J Gastroenterol 2006; 12:6594-6601. [PMID 17075970]
29. Karsen A, Beruhard JE, Flibotte S, Gelmon K, Switzer P, Hassell P, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem 2005; 51:1525-1528. [PMID 15951319]
30. Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE, Beijnen JH. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest 2007; 87:161-172. [PMID 17318195]
31. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003; 3: 2310-2316. [PMID 14673781]
32. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004; 84:845-856. [PMID 15107802]